2026-04-22T21:00:21Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/28682023-05-30T11:05:30Zcom_10324_1138com_10324_931com_10324_894col_10324_1226

Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limbischaemia Belch, Jill J.F. Hiat, William R. Baumgartner, Iris Vickie Driver, I. Nikol, Sigrid Largen, Lars Vaquero Puerta, Carlos Isquemia articular-tratamiento Background Patients with critical limb ischaemia have a high rate of amputation and mortality. We tested the hypothesis that non-viral 1 fi broblast growth factor (NV1FGF) would improve amputation-free survival. Methods In this phase 3 trial (EFC6145/TAMARIS), 525 patients with critical limb ischaemia unsuitable for revascularisation were enrolled from 171 sites in 30 countries. All had ischaemic ulcer in legs or minor skin gangrene and met haemodynamic criteria (ankle pressure <70 mm Hg or a toe pressure <50 mm Hg, or both, or a transcutaneous oxygen pressure <30 mm Hg on the treated leg). Patients were randomly assigned to either NV1FGF at 0·2 mg/mL or matching placebo (visually identical) in a 1:1 ratio. Randomisation was done with a central interactive voice response system by block size 4 and was stratifi ed by diabetes status and country. Investigators, patients, and study teams were masked to treatment. Patients received eight intramuscular injections of their assigned treatment in the index leg on days 1, 15, 29, and 43. The primary endpoint was time to major amputation or death at 1 year analysed by intention to treat with a log-rank test using a multivariate Cox proportional hazard model. This trial is registered with ClinicalTrials.gov, number NCT00566657. Findings 259 patients were assigned to NV1FGF and 266 to placebo. All 525 patients were analysed. The mean age was 70 years (range 50–92), 365 (70%) were men, 280 (53%) had diabetes, and 248 (47%) had a history of coronary artery disease. The primary endpoint or components of the primary did not diff er between treatment groups, with major amputation or death in 86 patients (33%) in the placebo group, and 96 (36%) in the active group (hazard ratio 1·11, 95% CI 0·83–1·49; p=0·48). No signifi cant safety issues were recorded. Interpretation TAMARIS provided no evidence that NV1FGF is eff ective in reduction of amputation or death in patients with critical limb ischaemia. Thus, this group of patients remains a major therapeutic challenge for the clinician. 2013-05-29T11:55:02Z 2013-05-29T11:55:02Z 2011 info:eu-repo/semantics/article Lancet, June, vol.377, june 4 p.1929-37 http://uvadoc.uva.es/handle/10324/2868 10.1016/S0140-6736(11)60394-2 1929 4 1937 Lancet 377 eng https://www.sciencedirect.com/science/article/pii/S0140673611603942 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/3.0/es/ Lancet Publishing Group Attribution-NonCommercial-NoDerivs 3.0 Unported Lancet Publishing Group SI